Diabetic ketoacidosis (DKA) is characterized by a pathologic
imbalance of insulin deficiency and catecholamine/glucagon excess.
This imbalance results in themetabolic complications of hyperglycemia,
metabolic acidosis, and ketoacidosis [1,2]. It is a common complication
of patientswith diabetesmellitus (DM), accounting for 9% to 28%
of all diabetes-related hospital admissions [1]. More than 100 000
patients yearly are admitted with DKA to US hospitals, resulting in
significant treatment costs